Duration of first-line antiretroviral therapy in HIV-infected treatment-naive patients in routine practice

• Published in: Antiviral therapy 2016-01, Vol.21 (8), p.715-724
• Main Authors: Tesson, Thomas, Blot, Mathieu, Fillion, Aurélie, Djerad, Hama, Cagnon-Chapalain, Joséphine, Creuwels, Aline, Waldner, Anne, Duong, Michel, Buisson, Marielle, Mahy, Sophie, Chavanet, Pascal, Piroth, Lionel
• Format: Article
• Language: English
• Subjects: Adult; Anti-HIV Agents - adverse effects; Anti-HIV Agents - therapeutic use; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections - drug therapy; HIV Infections - immunology; HIV Infections - virology; Humans; Lentivirus; Male; Middle Aged; Retroviridae; Time Factors
• ISSN: 1359-6535; 2040-2058
• DOI: 10.3851/IMP3084

First-line antiretroviral therapy (1st ART) is an important step in a patient's management and often considered a long-term therapy at treatment initiation. To describe the duration of 1st ART and the factors associated with treatment modification in a recent real-life setting, antiretroviral-naive patients who began their 1st ART in six French hospitals in 2009-2012 were included in a cohort. Clinical, immunological, virological and therapeutic data, as well as the reasons for therapeutic changes, if any, were retrospectively collected. A total of 206 patients started 1st ART, mainly a protease inhibitor-based triple therapy (73%), with a tenofovir-including backbone (87%). Of these, 89 (43%) had their 1st ART modified after a median of 16.5 months (IQR 8.0-32.8). Having a CD4 T-cell count